Pharmacologic treatment of cognition in Alzheimer's dementia

Neurology

Volumn 51, Issue 1 SUPPL., 1998, Pages

  Farlow, Martin R ^a   Evans, Rebecca M ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHOLINESTERASE INHIBITOR; ESTROGEN;

ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ARTICLE; CHOLINERGIC ACTIVITY; CHOLINESTERASE INHIBITION; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL;

EID: 0031880348     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.1_suppl_1.s36     Document Type: Article

References (107)

1. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:481-487.
2. Price DL, Sisodia SS. Cellular and molecular biology of Alzheimer's disease and animal models. Ann Rev Med 1994;45: 435-446.
3. Selkoe DJ. Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem 1996;27:18295-18298.
4. Yen SH, Liu WK, Hall FL, Yan SD, Stern D, Dickson DW. Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Neurobiol Aging 1995; 16:3:381-387.
5. Masliah E. Mechanisms of synaptic degeneration in Alzheimer's disease. Histol Histopathol 1995;10:509-519.
6. Larner AJ. The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis. Dementia 1995;6:218-224.
7. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994;151:1105-1113.
8. Zhou Y, Richardson JS, Mombourquette MJ, Weil JA. Free radical formation in autopsy samples of Alzheimer and control cortex. Neurosci Lett 1995;195:89-92.
9. Tonnaer JA, Dekker WC. Nerve growth factor, neurotrophic agents and dementia. In: Nicholson DG, ed. Anti-dementia agents: research and prospects for therapy. London: Academic Press, 1994;139-165.
10. McEwan BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol 1994;29:431-436.
11. Perry EK, Tomlinson BE, Blesses G, et al. Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia. BMJ 1978;2:1457-1459.
12. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease. Drugs 1997;53:752-768.
13. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
14. Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7, 1989. Rockville, MD: Dept of Health and Human Services, Public Health Service, Food and Drug Administration, 1989:227.
15. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48(5 Suppl 6):S10-6.
16. Reisberg M, Ferris SH. CIBIC-plus Interview Guide. New York: New York University, 1994.
17. Hughs CD, Berg L, Danziger L, Coben LA, Martin RL. A new rating scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
18. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther 1988;139:1136-1139.
19. Gauthier L, Gauthier S, Gelinas I, McIntyre M, Wood-Dauphinee S. Assessment of functioning and ADL [abstract]. Proc Sixth Cong Psychogeriatr Assoc 1993:9.
20. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990;11:29-37.
21. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
22. Heyman A, Schmechel D, Wilkonson W, et al. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease. J Neural Transm 1987;24(suppl):279-1286.
23. Nordberg A, Nilsson-Hakansson L, Adem A, et al. The role of nicotine receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res 1989;79:353-362.
24. 3H]ACh release from mouse cerebral cortical synaptosomes. J Neurochem 1984;43:1593-1598.
25. Sjak-Shie NN, Burks JN, Meyer EM. Long-term actions of nicotinic receptor stimulation in nucleus basalis lesioned rats: blockade of transsynaptic cell loss. In: Nagatsu T, Fisher A, Yoshida M, eds. Advances in behavioral biology. New York: Plenum Press, 1990:471-475.
26. Hodges H, Sinden J, Turner JJ, Netto CA, Sowinski P, Gray JA. Nicotine as a tool to characterize the role of the forebrain cholinergic projection system in cognition. In: Lippiello PM, Collins AC, Gray JA, Robinson JA, eds. The biology of nicotine: current research issues. New York: Raven Press, 1992: 157-182.
27. Buccafusco JJ, Jackson WJ. Beneficial effects of nicotine administered before a delayed-matching-to-sample task in young and aged monkeys. Neurobiol Aging 1991;12:233-238.
28. Levin ED. Nicotinic systems and cognitive function. Psychopharmacology 1992;108:417-431.
29. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 1996;35:42:13568-13578.
30. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994;13:131-144.
31. Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharm Biochem Behav 1995;51:509-514.
32. Snaedal J, Johannesson T, Jonsson JE, Gylfadottir G. The effects of nicotine in dermal plaster on cognitive function in patients with Alzheimer's disease. Dementia 1996;7:47-52.
33. Berman HA, Leonard K. Interaction of tetrahydroaminoacridine with acetylcholinesterases and butyrylcholinesterase. Mol Pharmacol 1992;41:412-418.
34. Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995;274:767-770.
35. Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-727.
36. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetra hydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315: 1241-1245.
37. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
38. Farlow MR, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, for the Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2529.
39. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 1990;322:1272-1276.
40. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1993;271:985-991.
41. Rogers SL, Yaminishi Y, Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991;314-320.
42. Donepezil package insert.
43. Rogers SL, Farlow MR, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
44. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996;8: 109-116.
45. Corey-Bloom J. The efficacy and safety of ENA-713 in patients with mild to moderately severe Alzheimer's disease [abstract]. J Am Geriatr Soc 1998;April.
46. Morris J, Cyrus P, Orazem J, Mas J, Bieber F, Gulanski B. Metrifonate: potential therapy for Alzheimer's disease [abstract]. Neurology 1997;48:1730.
47. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990;19:425-434.
48. Cummings J. Metrifonate: overview of safety and efficacy. Pharmacotherapy 1998;18:43-46.
49. Becker RE, Colliver JA, Markwell SJ, et al. Double blind placebo control study of metrifonate, an acetylcholinesterase inhibitor of Alzheimer's disease. Alzheimers Dis Assoc Disord 1996;10:124-131.
50. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 1994;37:1-11.
51. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-177.
52. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Rapid communication: differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995;64:1888-1891.
53. Giacobini E. Cholinergic receptors in human brain: effects of aging and Alzheimer's disease. J Neurochem Res 1990;27: 548-560.
54. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 1991;11:3218-3225.
55. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer's amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258:304-307.
56. DeLapp NW, Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci 1995;57:1183-1190.
57. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
58. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991;88: 10540-10543.
59. Smith MA, Perry G, Richey PL, et al. Oxidative damage in Alzheimer's. Nature 1996;382:120-121.
60. Sano M, Ernesto C, Thomas RG, et al; for the members of Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
61. Bishop J, Simplins JW. Estradiol enhances brain glucose uptake in ovariectomized rats. Brain Res Cull 1995;36:315-320.
62. Bishop J, Simpkins JW. Role of estrogens in peripheral and cerebral glucose utilization. Rev Neurosci 1992;3:121-137.
63. Ferreira A, Caceres A. Estrogen-enhanced neurite growth: evidence for a selective induction of tau and stable microtubules. J Neurosci 1991;11:392-400.
64. Diaz H, Lorenzo A, Carrer HF, Caceres A. Time lapse study of neurite growth in hypothalamic dissociated neurons in culture: sex differences and estrogen effects. J Neurosci Res 1992;33:266-281.
65. Lustig RH. Sex hormone modulation of neural development in vitro. Horm Behav 1994;28:383-395.
66. Naftlin F, Leranth C, Perez J, Garcia-Segura LM. Estrogen induces synaptic plasticity in adult primate neurons. Neuroendocrinology 1993;57:935-939.
67. Luine V. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985;89:484-490.
68. Kaufman H, Vadasz C, Lajtha A. Effects of estradiol and dexamethasone on choline acetyltransferase activity in various rat brain regions. Brain Res 1988;453:389-392.
69. Belfort MA, Saade GR, Snabes M, et al. Hormonal status affects the reactivity of the cerebral vasculature. Am J Obstet Gynecol 1995;172:1273-1278.
70. Ohkura T, Teshima Y, Isse K, et al. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause 1995;2:13-18.
71. Funk JL, Mortel KF, Meyer JS. Effects of estrogen replacement therapy on cerebral perfusion and cognition among postmenopausal women. Dementia 1991;2:268-272.
72. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid beta-precursor protein. J Biol Chem 1994;269:13065-13068.
73. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996; 156:2213-2217.
74. Morrison A, Resnick S, Corrada M, Zonderman A, Kawas C. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease in the Baltimore longitudinal study of aging [abstract]. Neurology 1996;46(suppl 2):A435-436.
75. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
76. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci 1995;7:334-337.
77. Lerner A, Cole R, Debanne S, et al. Immunological and endocrine conditions in an Alzheimer's disease case-control study [abstract]. Neuroepidemiology 1995;14:307.
78. Birge SJ. The role of estrogen deficiency in the aging central nervous system. In: Lobo RA, ed. Treatment of postmenopausal women: basic and clinical aspects. New York: Raven Press, 1994:153-157.
79. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women: comparison between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896-900.
80. Fillet H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia (Alzheimer's type). Psychoneuroendocrinology 1986;11:337-334.
81. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem Mol Biol 1989;34:521-525.
82. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997;48(suppl 7):S36-41.
83. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46: 1580-1584.
84. Bauer J, Strauss S, Schreiter-Gasser U. Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices. FEBS Lett 1991;285:111-114.
85. Eikelenboom P, Hack CE, Kamphorst W, Rozemuller JM. Distribution pattern and functional state of complement proteins and α1-antichymotrypsin in cerebral β/A4 deposits in Alzheimer's disease. Res Immunol 1992;143:617-620.
86. Ishii T, Haga S. Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol (Berl) 1984;63:296-300.
87. McGeer PL, McGeer EG. Complement proteins and complement inhibitors in Alzheimer's disease. Res Immunol 1992; 143:621-624.
88. Rozenmuller JM, van der Valk P, Eikelenboom P. Activated microglia and cerebral amyloid deposits in Alzheimer's disease. Res Immunol 1992;143:646-649.
89. Perlmutter LS, Scott SA, Barron E, Chui HC. MHC class II-positive microglia in human brain: association with Alzheimer's lesions. J Neurosci Res 1992;33:549-558.
90. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432.
91. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-632.
92. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43: 1609-1611.
93. Aisen PS, Marin D, Altsteil L, et al. A pilot study of prednisone in Alzheimer's disease. Dementia 1996;7:201-206.
94. Vane J. Towards a better aspirin. Nature 1994;367:215-216.
95. O'Banion MK, Winn VD, Young DA. CDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase, Proc Natl Acad Sci USA 1992;89:4888-4892.
96. Cao C, Matsumura K, Yamagata K, Watanabe Y. Induction by lipopolysaccaride of cyclooxygenase-2 mRNA in rat brain: its possible role in the febrile response. Brain Res 1995;697: 187-196.
97. Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer's disease. Neurology 1997;48(suppl 6): S35-41.
98. Lerea LS, Macnamara JO. Inotropic glutamate receptor subtypes activate c-fos transcription by distinct calcium-requiring intracellular signaling pathways. Neuron 1993;10:31-41.
99. Frederickson RCA, Brunden KR. New opportunities in AD research: role of immunoinflammatory responses and glia. Alzheimers Dis Assoc Disord 1994;8:159-165.
100. Schneider LS, Farlow MR. Predicting response to cholinergic inhibitors in Alzheimer's disease. CNS Drugs 1995;4:114-124.
101. Canal N, Imbimbo BP, Lucchelli PE, for the Eptastigmine Study Group. A 25-week, double-blind, placebo-controlled, trial of eptastigmine in patients with diagnosis of probable Alzheimer's disease. Eur J Neurol 1996;3(suppl 5):238.
102. Farlow MR, Brashear A, Hui S, et al. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease. Neurobiol Aging 1994;15(suppl 4):331.
103. Schneider LS, Farlow MR. Severity of Alzheimer's disease and response to cholinergic therapy. Eur J Neurol 1996; 3(suppl 5):238.
104. Levy R, Eagger S, Griffiths M, et al. Lewy bodies and response to tacrine in Alzheimer's disease [letter]. Lancet 1994;343:176.
105. Wilcock GK, Scott M, Pearsall T. Long-term use of tacrine [letter]. Lancet 1994;343:294.
106. Poirier J, Delisle M-C, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 1995;92:12260-12264.
107. Farlow MR, Lahiri D, Hui S, Davignon J. Apolipoprotein E genotype predicts response to tacrine in Alzheimer's disease [abstract]. Neurology 1996;46(suppl 2):A217.